Does the multidrug-resistance modulator cyclosporin A increase the cardiotoxicity of high-dose anthracycline chemotherapy?

Acta Oncologica

Volumn 36, Issue 7, 1997, Pages 735-740

  Eising, Ernst G ^a,c   Gries, Pascal ^a   Eggert, Jochen ^b   Scheulen, Max E ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c Clin and Policlinic for Nucl Med   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DOXORUBICIN; EPIRUBICIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA; CARDIOTOXICITY; CLINICAL ARTICLE; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY; SARCOMA;

EID: 0031417095     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869709001347     Document Type: Article

References (29)

1. Booser DJ, Hortobagyi GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 1994; 47: 223-58.
2. Sokolove PM. Inhibition by cyclosporin A and butylated hydroxytoluene of the inner mitochondrial membrane permeability transition induced by adriamycin aglycones. Biochem Pharmacol 1990; 40: 2733-6.
3. Kolar F, MacNaughton C, Papousek F, Korecky B. Systolic performance of heterotopically transplanted hearts in rats treated with cyclosporin. Cardiovasc Res 1993; 27: 1244-7.
4. von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Int Med 1979; 91: 710-7.
5. Goodman J, Hochstein P. Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochem Biophys Res Comm 1977; 77: 797-803.
6. Chabner BA, Collins JM: Cancer chemotherapy: principles and practice. Philadelphia: Lippincott, 1990.
7. Allen A. The cardiotoxicity of chemotherapeutic drugs. Sem Oncol 1992; 19: 529-42.
8. Schwartsmann G, Dekker AW, Verhoff J: Complications of cytotoxic therapy. In: Peckham M, Pinedo H, Veronesi U, eds. Oxford Textbook of Oncology. Oxford: Oxford University Press, 1995; Vol. 2.
9. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978; 62: 873-9.
10. Treat J, Greenspan A, Forst D, Sanchez JA, Ferrans VJ, Potkul LA, Woolley PV, Rahmen A. Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst 1990; 82: 1706-10.
11. Basser RL, Green MD. Complications of treatment: Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat Rev 1993; 19: 57-77.
12. Carlson RW. Reducing the cardiotoxicity of the anthracyclines. Oncology Williston Park 1992; 6: 95-100, 104, discussion 107-8.
13. Doroshow JH. Doxorubicin-induced cardiac toxicity. New Engl J Med 1991; 324: 843-5.
14. Brown KA, Blow AJ, Weiss RM, Stewart JA. Acute effects of doxorubicin on human left ventricular systolic and diastolic function. Am Heart J 1989; 118: 979-82.
15. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the cardiology committee of the childrens cancer study group. Pediatrics 1992; 89: 942-9.
16. Adam WF, Clausen M, Hellwig D, Henze E, Bitter F. Radionuclide ventriculography (equilibrium gated blood pool scanning) - its present clinical position and developments. Eur J Nucl Med 1988; 13: 637-47.
17. Corbett JR, Jansen DE, Willerson JT. Radionuclide ventriculography. Am J Physiol Imaging 1987; 2: 33-43, 85-104.
18. Felipe RF, Prpie U, Arndt JW, van der Wall EE, Pauwels EK. Role of radionuclide ventriculography in evaluating cardiac function. Eur J Radiol 1991; 12: 20-9.
19. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Am J Med 1987; 82: 1109-18.
20. McKillop JU, Bristow MR, Goris MF, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxoruhicin cardiotoxicity. Am Heart J 1983; 106: 1048-56.
21. Parmentier S, Melin JA, Piret L, Beckers C. Assessment of left ventricular diastolic function in patients receiving anthracycline therapy. Eur J Nucl Med 1988; 13: 563-7.
22. Pauwels FKJ, Feitsma RIJ, Blom J. Influence of adriamycin on red blood cell labelling: a pitfall in scintigraphic blood pool imaging. Nucl Med Comm 1983; 4: 290-3.
23. Solem LE, Wallace KB. Selective activation of the sodium-independent, cyclosporin A-sensitive calcium pore of cardiac mitochondria by doxorubicin. Toxicol Appl Pharmacol 1993; 121: 50-7.
24. Kadmon M, Klünemann C, Böhme M, Ishikawa T, Gorgas K, Otto G, Herfarth C, Keppler D. Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. Gastroenterology 1993; 104: 1507-14.
25. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-42.
26. Erlichmann C, Moore M, Thiessen JJ, Ken IG, Walker S, Goodman P, Bjarnason G, DeAngelis C, Bunting P. Phase I pharmacokinetic study of cyclosporine A combined with doxorubicin. Cancer Res 1993; 53: 4837-42.
27. List AF, Spier CM, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. Phase I II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652-60.
28. Yahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1992; 10: 1624-34.
29. Scheulen MH, Eggert J, Schütte J, Budach W, Aunweiler H, Mengelkoch B, Borquez D, Skorzec M, Wiefelspütz J, Saek H, Seeber S. Influence of cyclosporin A on the pharmacokinetics and pharmacodynamics of doxorubicin and epirubicin. Onkologie 1993; 16 (Suppl 1): 9.